

# Index

- 5HTT gene polymorphisms, 762  
 5-HTTLPR gene, 430
- Aanat* gene, 430
- Abbott Concussion IQ Survey, 100
- abbreviations, 683t20.1
- acceleration forces in CBI, 139
- acetyl-CoA  
   role in CBI pathophysiology, 140, 141, 143
- Achenbach Adult Behavior Checklist (ABCL), 445
- Achenbach Behavior Checklists, 218
- Achenbach System of Empirically Based Assessment, 290
- Acquired Capability for Suicide Scale, 436
- Acute Concussion Evaluation (ACE), 653
- Adams, Francis, 36–37
- adenosine  
   role in the homeostatic sleep drive, 757
- adenosine triphosphate (ATP), 762  
   consumption/production imbalance following CBI, 140
- adrenocorticotrophic hormone (ACTH), 775  
   deficiency symptoms, 768t26.1
- adrenocorticotrophin (ACTH), 767
- Advanced Trauma Life Support/ American College of Cardiology (ATLS/ACS) guidelines on CT scan after concussion, 602
- Affective Liability Scale, 384
- age  
   risk factor for CBI, 101  
   risk factor for poor outcomes of CBI, 343–45  
   risk factor for sports concussion, 111–12
- aggressive behavior  
   assessment in concussion patients, 385  
   in concussion patients, 385–86  
   epidemiology, 446  
   incidence after TBI, 385  
   irritability after trauma, 385  
   personality change after TBI, 385  
   treatments for concussion patients, 385–86
- aging  
   antagonistic pleiotropy theory of aging, 505  
   attempts to distinguish from Alzheimer's disease, 520–25  
   defining, 502–7  
   disposable soma theory of aging, 505  
   force-of-mortality factors, 505  
   history of changing human life expectancy, 503  
   lack of universally agreed definition, 502–3  
   phenoptosis theory of aging, 505  
   programmed theory of aging, 503–4  
   stochastic (chance) theory of aging, 504–5  
   theories of aging, 503–5  
   time-passing-related life-history concept, 505–7
- agitation  
   following TBI, 444
- alcohol  
   enhanced response after TBI, 751  
   use/abuse in TBI patients, 751
- all-terrain vehicle riding  
   concussion risk, 114
- Allen Human Brain Atlas project, 68
- Altman, Joseph, 173
- Alzheimer's disease, 639  
   Alzheimer's original description, 513–14  
   APOE  $\epsilon$ 4 allele risk factor, 313–15  
   attempts to distinguish from aging, 520–25  
   case of Auguste Deter, 501, 513–14, 517  
   conflicting results from TBI studies, 512–13  
   defining, 512–26  
   distinguishing between aging and AD, 514–17  
   fallacy of attributing causality to biomarkers, 517  
   inflammation and activated microglia, 519–20  
   physiological and pathological roles of amyloid beta, 517–20  
   proliferation of competing diagnostic criteria, 514–17  
   questioning its existence as a natural kind, 525–26  
   risk after earlier CBI(s), 329–35
- Alzheimer's Disease Neuroimaging Initiative (ADNI), 559
- amantadine, 385, 386, 753  
   use in post-concussive aggression, 451
- American Academy of Neurology (AAN)  
   consensus definition of concussion, 81–82  
   guideline on CT scan after concussion, 603
- American College of Emergency Physicians (ACEP)  
   guideline on CT scan after concussion, 600–1
- American College of Rehabilitation Medicine (ACRM)  
   diagnostic criteria for CBI, 95–96
- American College of Sports Medicine (ACSM), 646  
   definition of concussion, 82–83
- American Medical Association Guides to the Evaluation of Permanent Impairment (GEPI), 738–39
- American Medical Society Sports Medicine Position Statement on Concussion and Sports, 729
- American Neuropsychiatric Association, 416
- American Psychiatric Association (APA), 346, 347, 403
- AMPA receptor binding in CBI, 139
- amygdala, 388, 389, 392  
   functions, 179  
   response to aversive and safety cues, 392  
   vulnerability to concussion, 179–82
- amyloid beta (A $\beta$ )  
   aggregation and plaque formation, 639  
   disruption caused by TBI, 331–32  
   pathology after TBI, 575–76  
   physiological and pathological roles, 517–20  
   potential influential factors in TBI pathology, 576  
   role in neurodegeneration, 168–71
- amyloid precursor protein (APP), 168  
   transgenic mice, 169
- amyloid-related processes  
   CSF biomarkers, 640–41
- amyotrophic lateral sclerosis (ALS), 171, 537
- anger  
   following TBI, 444
- anger management  
   approaches, 449
- anger self-management programs, 385
- animal models of concussion  
   abnormal activity of dysfunctional neurons, 180, 187  
   Alzheimer's disease does not occur in rodents, 168–71  
   association between concussion and later dementia, 188  
   Barnes maze, 166  
   beam walking test, 165  
   behaviors assessed are not comparable in humans, 165–67

## Index

- animal models of concussion  
 (*cont.*)  
 behaviors assessed  
 lack ecological  
 validity, 165–67  
 blast injury models, 162–63  
 Closed Head Injury  
 Model of Engineered  
 Rotational Acceleration  
 (CHIMERA), 162–63, 164  
 competing helpful and  
 harmful brain  
 change, 178–79  
 concussive force does not  
 predict the degree of  
 brain injury, 156–58  
 Controlled Cortical Impact  
 Model (CCI), 160–64  
 damage to areas associated  
 with functional  
 deficits, 179–82  
 defining brain injury, 180  
 detecting neuron death in  
 ‘mild’ injuries, 183–85  
 detecting neuron death in  
 moderate to severe  
 injuries, 182–83  
 disproportionate damage  
 to certain brain  
 cells, 179–82  
 early animal experiments, 45  
 ethical issues, 162  
 experiments with abrupt  
 external force, 154–55  
 failure to replicate  
 typical human  
 concussion, 159–65  
 Fluid Percussion Injury Model  
 (FPI), 160–61, 162–64  
 force best approximating  
 human concussion is not  
 known, 156–58  
 fragile brain structures  
 associated with  
 post-concussion  
 neurobehavioral  
 problems, 179–80  
 genetic variation and post-CBI  
 gene expression, 187–88  
 hitting the wrong thing in the  
 wrong way, 159–65  
 Impact Acceleration Injury  
 Model (IAI), 160–61  
 inability to know how  
 animals feel after  
 concussion, 165  
 inability to study persistent  
 problems, 167–68  
 individuality of humans  
 is not considered in  
 animals, 155  
 issues relating to sedation, 162  
 key questions for animal  
 studies, 153–54  
 lack of investigation of late  
 effects, 154–55  
 lack of long-term  
 studies, 167–68  
 limits of optical microscope  
 detection of brain  
 change, 176–78  
 medium- to long-term  
 studies, 188–96  
 methodological issues, 8  
 Morris Water Maze, 166  
 naturalistic assessments, 167  
 neurobiological melee of  
 concussion, 178–79  
 neurodegenerative  
 features, 168–71  
 neurogenesis, 171–76  
 neurogenesis found in  
 rodents, 156  
 neuron death, 182–88  
 parts of the brain damaged in  
 mice and humans, 179  
 parts of the brain damaged in  
 milder concussions, 179  
 persistence of brain  
 changes, 180  
 popular experimental  
 models, 159–65  
 post-concussive memory  
 tests, 166–67  
 problems with animal  
 models, 155–78  
 progressive  
 neurodegeneration, 180  
 questionable relevance to  
 human concussion, 153  
 Radial Arm Maze, 166  
 role of connectivity in brain  
 cell survival, 187  
 Rotarod test, 166  
 significance of neuronal  
 loss, 185–88  
 standardization  
 versus individual  
 variability, 159–60  
 T-Maze, 166  
 use of species which never  
 develop Alzheimer’s  
 disease, 156  
 use of transgenic mice, 169  
 Weight Drop Acceleration  
 Injury Model  
 (WDAI), 160–61  
 what they reveal, 178–96  
 anosognosia, 216  
 anterior cingulate cortex  
 (ACC), 388  
 anterior cingulate gyrus, 179  
 anticonvulsants, 390  
 antidepressants, 389  
 antidiuretic hormone  
 (ADH), 751  
 APOE genotype  
 arguments for and against  
 testing, 313–18  
 ethical conditions for  
 disclosure, 315  
 influence on CBI  
 outcomes, 313  
 risks in childhood, 315–18  
 APOE polymorphisms, 168  
 APOE  $\epsilon 4$  allele  
 health risks associated with, 313  
 pleiotropic effects, 505  
 possible influences on TBI  
 outcome, 310–11  
 risk factor for Alzheimer’s  
 disease, 313–15  
 susceptibility to chronic  
 traumatic brain injury in  
 boxers, 313–14  
 APOE  $\epsilon 4$  carriers  
 functional neuroimaging of  
 TBI, 565–66  
 neuroimaging of TBI, 567–68  
 Applied Behavioral Analysis  
 (ABA), 753  
 Aqapendente, Fabricius ab, 40  
 arginine vasopressin (AVP), 767,  
 773  
 deficiency symptoms,  
 768t26.1  
 aripiprazole, 385, 390  
 Aristotle, 499, 500  
 arterial dissections  
 headache associated with, 735  
 ASPA gene, 141  
 aspartate N-acetyl  
 transferase, 140  
 aspartoacylase (ASPA), 141  
 assessment tools, 216–18  
 astroglial injury  
 CSF biomarkers, 640  
 athletes  
 pressures not to report  
 concussion and  
 symptoms, 25–26  
 atypical antipsychotics, 390  
 Auburtin, A., 293  
 authority  
 misplaced faith in, 14  
 Automated Neuropsychological  
 Assessment Metrics  
 (ANAM), 656, 675  
 automobile accidents  
 traumatic brain injuries, 50  
 autonomic nervous system (ANS)  
 changes in the changes in TBI  
 and PTSD, 392  
 role in sleep regulation, 757  
 axonal injury  
 CSF biomarkers, 640  
 diffuse axonal injury, 639  
 finite element (FE)  
 modeling, 266  
 maximal axonal strain  
 measurement, 302  
 spectrum of injuries in  
 CBI, 59–63  
 white matter damage in  
 TBI, 262–63  
 axonal stretch in TBI  
 disruption of amyloid  
 beta, 331–32  
 disruption of tau, 332–34  
 Babinski, Joseph, 338  
 Balance Error Scoring System  
 (BESS), 648, 658,  
 673–75, 728  
 Baragazzi, Jacobo, 39–38  
 Barnes Maze, 166  
 Barroso Fatigue Scale (BFS), 748  
 Barrow Neurological Institute  
 (BNI) Fatigue Scale,  
 744t24.2  
 Overall Severity Index  
 Score, 748t24.2  
 baseball  
 concussion risk, 114  
 basketball  
 concussion risk, 114  
 Bayer, Shirley, 173  
 BDNF gene, 392, 434  
 polymorphisms, 762  
 val66met polymorphism, 387  
 beam walking test, 165  
 Beck Depression Inventory-II, 688  
 Beckett, William, 42–43  
 Behavioral Modification  
 Therapy, 449  
 Behavioral Neurology &  
 Neuropsychiatry  
 certification, 416  
 Bell, Benjamin, 43  
 Bender Visual Motor Gestalt  
 test, 403  
 Benson, D. Frank, 79, 328, 348, 404  
 Benton, Arthur, 403  
 Betz, Vladimir, 45–46  
 bicycling  
 concussion risk, 114–18  
 Bigler, Erin  
 Distinguished  
 Neuropsychologist  
 Award Lecture, 18–19  
 Binet, Alfred, 403  
 biomarkers  
 fallacy of attributing causality  
 to, 517  
 individualized neuroimaging  
 biomarker  
 detection, 274–77  
 biomarkers for concussion  
 biomarkers for chronic brain  
 changes after TBI, 642  
 candidate biomarkers for  
 CBI, 9–10  
 chronic traumatic  
 encephalopathy  
 (CTE), 639  
 CSF biomarkers, 639–41  
 CSF biomarkers for  
 amyloid-related  
 processes, 640–41  
 CSF biomarkers for astroglial  
 injury, 640  
 CSF biomarkers for axonal  
 injury, 640  
 CSF biomarkers for  
 neuroinflammation, 640  
 CSF biomarkers for neuronal  
 injury, 640  
 CSF/serum albumin  
 ratio, 639–40  
 definition of biomarker, 639  
 definition of concussion or  
 mTBI, 639

- fluid biomarkers for brain injury, 639  
 future research, 642–43  
 indicators of blood-brain barrier (BBB) function, 639–40  
 pathophysiology of concussion, 639  
 peripheral blood biomarkers for acute brain injury, 641–42  
 persistent symptoms of concussion, 639  
 risk factors for CTE, 639  
 symptoms of CTE, 639  
 upcoming CSF biomarkers for TBI, 641  
 biopsychosocial conceptualization of CBI, 684–85  
 bipolar disorder  
   possible risk factor for TBI, 387–88  
 BIRC3 gene, 145  
 Bismarck, Otto von, 48, 348  
 blast injury concussion, 53  
   animal models, 162–63  
 blood biomarkers for acute brain injury, 641–42  
 blood-brain barrier (BBB)  
   biomarkers of BBB function, 639–40  
 Bnip3 gene, 145  
 BOLD response, 716–17  
 Bonet, T., 40  
 Boston Assessment of TBI-Lifetime, 687, 689  
 boxing  
   APOE  $\epsilon$ 4 allele and susceptibility to chronic traumatic brain injury, 313–14  
   concussion risk, 118  
   *See also* dementia pugilistica; punch-drunk syndrome, 529  
 Brain Injury Association of America, 694  
   definition of concussion, 83  
 brain injury medicine doctors  
   ability to care for concussion survivors, 416–17  
 brain-mind reciprocating trauma, 360  
 Brief Test of Adult Cognition, 528  
 Broca, Paul, 293, 401  
 Brodie, B.C., 44–45  
 Brodmann's areas of the brain, 292–93  
 Bryant, T., 44, 47  
 Buffalo Concussion Treadmill Test, 792  
 bupropion, 389  
 buspirone, 385  
 c-Fos, 762  
 caffeine  
   adenosine antagonist effect, 757  
   enhanced response after TBI, 751  
   Cajal bodies, 171  
   Calm3 gene, 145  
   Canadian CT Head Rule (CCHR), 599–600, 600t15.2, 603  
   candidate gene approach, 306  
   Cannon, Walter B., 49–50  
   carbamazepine, 385  
   carbidopa, 753  
   caregiver support, 389  
   cataplexy, 760  
   categorization  
   illogical approach to, 37  
   Caxton, William, 37  
   Ccl2 gene, 145  
   Cellini, Benevenuto, 39  
   Celsus, Aulus Cornelius, 39  
   Center for Epidemiological Studies-Depression Scale, 436  
   cervicogenic headache, 731–32  
   Charcot, Jean-Martin, 338  
   cheerleading  
   concussion risk, 118  
   Chen, AJ, 412  
   Child SCAT, 648  
   Child SCAT3, 653  
   childhood abuse  
   long-term effects on stress reactivity, 391  
   risk factor for adult PTSD, 391  
 children  
   concussion risks associated with APOE genotype, 315–18  
   choline, 74–75  
   MR spectroscopy, 271  
   chronic progressive traumatic encephalopathy, 582  
   chronic traumatic encephalopathy (CTE), 582, 639  
   Boston University CBI Research Group study (2017), 532–33  
   case of Michael Keck, 530  
   clarifying what it is and is not, 534–37  
   contemporary usage of the term, 527  
   defining, 526–40  
   diagnostic confusion and inconsistency, 535  
   distinguishing brain changes in the young from those in the old, 530–32  
   explaining CTE caused by repetitive trauma, 537  
   as a heterogeneous clinical phenomenon, 535  
   incidence of amyloid abnormalities, 535  
   incidence of polypathology in older brains exposed to multiple concussions, 533–34  
   inflammatory hypothesis of tauopathy development, 536  
   investigating the link with repeated CBI, 527–30  
   lack of clinico pathological correlation in some studies, 532–33  
   original meaning of traumatic encephalopathy, 526–27  
   polypathy labeled as, 527  
   produced by a single TBI, 535–37  
   relationship between repeated CBI and tauopathy, 534  
   risk after earlier CBI(s), 329–35  
   risk factors, 639  
   risk of tauopathy with repeated concussions, 534–35  
   role of tauopathy, 530–32  
   seeding hypothesis of tauopathy development, 536  
   spectrum of brain changes, 535  
   symptoms, 639  
   tauopathy, 527  
   TDP-43  
   proteinopathies, 537–38  
   vascular hypothesis of tauopathy development, 536  
   circadian rhythm, 757  
   citalopram, 385, 389  
   citric acid cycle, 141  
 Clinical Data Interchange Standards Consortium (C-DISC), 710  
 clinical decision support (CDS) systems, 613  
 Clinical Dementia Rating scale (CDR), 512  
 clinical psychologists  
   ability to care for concussion survivors, 417  
 Clinician-Administered PTSD Scale (CAPS), 459  
 Clinician-Administered PTSD Scale for the DSM-5 (CAPS-5), 391  
 Clock Drawing Test, 511  
 CLOCK gene, 761–62  
 clock gene  
   polymorphisms, 761–62  
 Closed Head Injury Model of Engineered Rotational Acceleration (CHIMERA), 162–63, 164  
 cognitive behavioral psychotherapy, 385  
 Cognitive Behavioral Therapy (CBT), 389, 449, 468, 469, 751  
 cognitive biases in symptom reporting, 346  
 cognitive development  
   effects of pediatric concussion, 654–55  
 cognitive domains  
   meaning of, 17  
 cognitive impairment  
   definition, 17  
 Cognitive Processing Therapy (CPT), 468, 469  
 cognitive rehabilitation  
   systematic review of research, 783–88  
 cognitive testing  
   effectiveness in assessing brain function, 21–22  
   misplaced faith in, 17–22  
 CogState battery, 675  
 Columbia Suicide Severity Rating Scale, 436  
 Common Data Elements (CDEs)  
   instruments, 445–46  
 Common Data Elements (CDEs)  
   project, 6, 217  
   Clinical Data Interchange Standards Consortium (C-DISC), 710  
   contribution to data management and analysis, 711  
   Federal Interagency TBI Research (FITBIR)  
   informatics system, 696–710  
   goals relating to TBI, 694  
   history and development, 694  
   implementation of TBI CDEs, 696–710  
   remaining limitations and caveats, 710–11  
   sport-related concussion outcomes, 696  
   Transforming Research and Clinical Knowledge in TBI (TRACK-TBI), 710  
   Version 1.0 TBI outcome measures, 694–95  
   Version 2.0 TBI outcome measures, 695–96  
*commotio cerebri* concept, 3, 35, 39  
 compensation issues in CBI, 348–55  
   controversy over 'litigation overlay', 351–53  
   creation of advocates and adversaries, 348–49  
   determining the effect on the misreporting of symptoms, 349–51  
   expansion of personal injury compensation, 51–52  
   influence of the views of Henry Miller, 351–53  
   means used to avoid injury compensation liability, 52–53  
   outcome is unknowable, 348  
   perverse incentives created by compensation systems, 348–49

## Index

- compensation issues in CBI (*cont.*)  
 proportion of compensation-seekers which exaggerates, 354–55  
 unique circumstances of each CBI, 353–54  
 victim blaming, 351–53  
 ways in which compensation systems might influence symptom reporting, 353–54
- compensation seeking  
 litigation overlay, 346
- compensation-system induced stress, 354
- Computerized Cognitive Assessment Tool (CCAT), 656
- COMT gene  
 polymorphisms, 762
- concussion  
 changing meanings over time, 156–57  
 defined as a mechanical force, 33  
 origins of association with ‘mild’, 37  
 use of the term in medicine, 33
- Concussion in Sport Group (CISG)  
 consensus statements, 15–16  
 definition of concussion, 82, 83
- Concussion Resolution Index (CRI), 656
- Concussion Vital Signs, 656, 675
- concussive brain injury (CBI)  
 controversy over persistent post-concussive symptoms, 1–2  
 defining, 33–35, 157  
 defining recovery, 78–79  
 diagnostic semantics, 79–80  
 diffuse injury, 34  
 efforts to produce consensus definitions, 80–84  
 long-term effects of injuries, 35–36  
 measuring the extent of the injury burden, 35–36  
 multifocal effects, 34  
 spectrum of harm, 34
- Congress of Neurological Surgeons  
 Committee on Head Injury Nomenclature, 80–81
- consensus groups  
 misplaced faith in, 14–16
- contact forces in CBI, 139
- Contingency Management Therapy, 449
- contrecoup injury, 43
- Controlled Cortical Impact Model (CCI), 160–64
- conversion disorder, 346, 347
- cortical-limbic disconnection model, 388
- cortisol deficiency, 775–76
- Courville, Cyril Brian, 3, 58
- COX-2 gene, 144
- craniomandibular syndrome  
 headache caused by, 731
- creatine, 74–75  
 MR spectroscopy, 273
- CREB (cyclic AMP response element binding protein), 181
- Creutzfeldt–Jakob disease, 170
- CSF biomarkers  
 for amyloid-related processes, 640–41  
 for astroglial injury, 640  
 for axonal injury, 640  
 for neuroinflammation, 640  
 for neuronal injury, 640  
 upcoming biomarkers for TBI, 641
- CSF/serum albumin ratio, 639–40
- CT scan after concussion  
 Advanced Trauma Life Support/American College of Cardiology (ATLS/ACS) guidelines, 602  
 American Academy of Neurology (AAN) guideline, 603  
 American College of Emergency Physicians (ACEP) guideline, 600–1  
 applications and limitations in CBI, 262–63, 408  
 Canadian CT Head Rule (CCHR), 599–600, 600t15.2  
 classification of scan results, 598–99  
 clinical decision support (CDS) systems, 613  
 considerations in decision making, 603  
 cost-benefit analysis, 595–96  
 CT cannot definitively diagnose CBI, 598–99  
 deciding whether or not concussion patients should have a CT scan, 595–96  
 definition of an unnecessary scan, 619–20  
 Eastern Association for the Surgery of Trauma (EAST) guideline, 601–2  
 ethics of withholding a scan, 623  
 health implications if carried out or not, 596–97  
 implications of a negative scan, 598–99  
 ineffectiveness of selection algorithms, 598–99  
 information required by patients, 620–21  
 informed consent, 622–23  
 intracranial lesion detection rate by CT in adults, 603–4
- limited information from research findings, 597–98
- National Institute for Health and Clinical Excellence (NICE) guideline, 603–5
- New Orleans Criteria (NOC), 600, 600t15.3
- New South Wales (NSW) protocol, 601–2
- objection based on cost, 618–19
- objection based on radiation exposure risk, 616–18
- objection to early scanning, 615–16
- ongoing debate, 596–97
- Ontario Neurotrauma Foundation (ONF) guidelines, 602
- patient participation in decision making, 621–22
- physicians’ non-compliance with protocols, 612–13
- proposed protocols, 599–605
- psychosocial influences on decision making, 613–15
- quality of studies, 608–11
- reassuring the patient, 621
- reliability of risk factor assessments, 611–12
- Scandinavian Neurotrauma Committee (SNC) protocol, 602–4
- scientifically defensible and ethical options, 623
- Scottish Intercollegiate Guides Network (SIGN) guideline, 601
- sensitivities and limitations of CT, 598–99
- significance of non-surgical intracranial lesions, 604–5
- studies used to determine CT protocols, 606–8
- Veterans Administration/Department of Defense (VA/DoD) guideline, 601
- what patients want, 620–23
- cytokines and sleep, 762
- da Carpi, Berengario, 39–38
- Damianus, Tertius, 40
- Darwin, Charles, 52, 305, 501–2
- Dax, Marc, 401
- Dear Leader Experiment, 214–16
- default mode network, 388
- Defense and Veterans Brain Injury Center (DVBIC), 6, 694
- defining CBI, 33–35  
 efforts to achieve consensus definitions, 80–84
- definitions  
 concussion as a mechanical force, 33  
 diffuse injury, 34  
 dehydration headache, 731
- dementia  
 amyloid beta pathology after TBI, 575–76  
 competing contemporary definitions, 510–11  
 defining, 509–12  
 factors influencing risk after TBI, 574  
 historical meaning of the term, 509–10  
 influence of disease pathology after TBI, 578  
 investigating the link with CBI, 511–12  
 late effects of CBI, 497–98  
 pathological protein accumulation after TBI, 574–75  
 polypathology after TBI, 578  
 potential contributing biological factors in TBI, 511  
 questions on the relationship with TBI, 511  
 tau pathology after TBI, 576–78  
 TBI risk factor, 573–74
- dementia pugilistica, 526, 529, 582, 639
- Dencker, Sven J., 220–21
- Denny-Brown, D.E., 56–58
- depression  
 definition, 427  
*See also* mood disorders; post-concussive depression, 427
- Descartes, René, 52, 328
- D’Esposito, M., 412
- dextroamphetamine, 389, 753
- diabetes insipidus, 751, 773
- diagnosis of concussion  
 approach to diagnosis, 672  
 Balance Error Scoring System (BESS), 673–75  
 clinical and laboratory tools, 675  
 diagnostic semantics, 79–80  
 diffusion tensor imaging (DTI), 678–79  
 electroencephalography (EEG), 678  
 event-related potentials (ERPs), 678  
 functional MRI (fMRI), 678–79  
 gait measures, 677  
 Military Acute Concussion Evaluation (MACE), 673  
 multi-modal concussion assessment battery, 677  
 neurophysiological assessment tools, 677–79  
 neuropsychological testing, 675–77  
 on-field evaluation, 672  
 problems with operational (non-biological) diagnostic criteria, 95–96



- Sensory Organization Test (SOT), 676  
 sideline tools, 672–75  
 Sport Concussion Assessment Tool - 3rd edition (SCAT-3), 675  
 Standardized Assessment of Concussion (SAC), 673  
 summary of assessment tools, 679–80  
 symptom checklists, 672–73  
 virtual reality (VR) testing environment, 676–77  
 diagnosis threat after CBI, 346  
 diaschisis, 295  
 diffuse axonal injury, 62, 263, 639  
 diffuse injury  
   definition, 34  
 diffusion tensor imaging (DTI), 62–63, 678–79  
 Diller, Leonard, 403  
 Disability Assessment Schedule 2.0 (WHO), 289, 357–58  
 disability payments  
   expansion of, 51–52  
 disease  
   changing conceptions of, 290–91  
 dopamine, 767  
 dorsal nucleus of the vagus nerve, 392  
 dorsolateral prefrontal cortex (DLPFC), 179, 389  
 dorsomedial thalamus, 392  
 dorsomedian thalamic nucleus, 388  
 drama of attribution, 348, 357–58  
 draw-a-person test, 403  
 drugs  
   use/abuse in TBI patients, 751  
 DSM-5, 346, 347  
   classification of mood disorders, 386  
 DSM system  
   problems with, 502  
 DTI (diffusion tensor imaging), 264, 265–66  
   ADC (apparent diffusion coefficient), 266–67  
   fractional anisotropy (FA), 266–70  
   hemosiderin detection, 269–75  
   role in CBI investigation, 267–75  
 dualism  
   resistance to the idea that brains mediate mental functions, 209  
   straw man issue, 328  
 dysautonomic headaches, 735  
 early brief interventions  
   systematic review of research, 791  
 early single session interventions  
   systematic review of research, 791  
 Eastern Association for the Surgery of Trauma (EAST)  
   guideline on CT scan after concussion, 601–2  
 Eban, Abba, 14  
 Ebbinghaus, Hermann, 401  
 Edwin Smith Surgical Papyrus, 38  
 effort-induced headache, 731  
 Eif4g2 gene, 145  
 electroconvulsive therapy (ECT), 389  
 electroencephalography (EEG), 678  
 electron transport chain, 141, 145  
 emotional distress  
   prioritizing emotions in neuropsychology, 415  
   stress vulnerability genes, 312–13  
 emotional disturbances  
   barriers to accurate incidence and prevalence  
   accounting after concussion, 387  
   characteristics of emotions, 383  
   complexity of human emotions, 383  
   disruption of prefrontal circuits by TBI and CBI, 384  
 emotional lability, 384–85  
 features of, 384  
 interplay of factors in TBI and CBI, 383  
 irritability and aggression, 385–86  
 lack of evidence for post-concussion syndrome, 383–84  
 new approaches and understandings, 383  
 pathophysiology associated with TBI and CBI, 383  
 post-concussive symptoms, 383–84  
 post-traumatic stress disorder (PTSD), 383  
 recognition that post-CBI brain change is common, 383  
 relation to the circumstances of the concussion, 384  
 role of the prefrontal cortex in emotional regulation, 384  
*See also* mood disorders; post-traumatic stress disorder (PTSD), 390  
 emotional lability, 384–85  
   Affective Lability Scale, 384  
   assessment, 384  
   change in personality pattern, 384  
   conditions associated with, 384–85  
 features of, 384  
 overlap with other disorders, 384–85  
 possible pharmacotherapies, 385  
 prevalence following concussion, 384  
 treatments for persistent emotional lability, 385  
 emotions  
   characteristics of, 383  
 Empedocles, 500  
 Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) study, 298–300  
 epidemiology of CBI  
   age risk factor, 101  
   causes, 102–3  
   CDC pyramid  
     barriers to complete accounting of CBI, 98–100  
     estimates of unreported concussions, 100  
     sources of the CDC figures, 97–100  
   CDC triangle  
     estimates of annual incidence of CBI, 100–1  
     estimates of lifetime cumulative incidence, 101  
     potential sources of numerical error, 100  
 human and health care costs, 128–29  
 implications of lack of data, 94–97  
 military concussion, 104–8  
 need for prospective, longitudinal, population-based studies, 129  
 problems with operational (non-biological) diagnostic criteria, 95–96  
 race/ethnicity and CBI risk, 102  
 risk factors for CBI, 101–3  
 risk of recurrence, 103–4  
 sex differences in CBI risk, 101–2  
 sports-related concussion, 108–28  
 unreported cases, 96  
 what counts as brain injury, 93–94  
 why prevalence of brain injury may never be known, 128–29  
 epigenetics, 306–7  
 epilepsy  
   post-traumatic, 387  
 epistasis, 306  
 Epworth Sleepiness Scale (ESS), 753  
 equestrian sports  
   concussion risk, 118–19  
 Erichsen, John, 44, 48, 49  
 escitalopram, 385  
 estrogen replacement therapy, 776  
 ethics  
   restraints on concussion research, 213–16  
 Evaluation of Lifetime Stressors, 687  
 event-related potentials (ERPs), 678  
 excitatory amino acids (EAAs), 139  
 exercise interventions  
   for post-CBI fatigue, 750  
   systematic review of research, 789–90  
 exertional headache, 730–31  
 expert witnesses  
   collective bargaining approach, 806  
   duties under the British system, 804  
   expert shopping by parties to litigation, 804–5  
   history of use of, 803–4  
   position in the U.S. legal system, 804–5  
   pressures on, 803  
   problem of biased experts in the U.S., 805  
   voluntary duty clause, 805–6  
 Eye Movement Desensitization and Reprocessing (EMDR), 469–71  
 Fabry, Wilhelm, 40  
 factitious disorder, 346  
 fatigue after concussion  
   anatomical considerations, 744–46  
   assessment, 747–48  
   behavioural/lifestyle interventions, 749–52  
   causal factors, 744  
   energy conservation, 751–52  
   enhanced response to alcohol, 751  
   enhanced response to caffeine, 751  
   environmental modifications, 752  
   epidemiology, 743–44  
   exercise interventions, 750  
   features of post-TBI fatigue, 743  
   fluid dysregulation after TBI, 751  
   genetic influences, 746  
   growth hormone deficiency, 746–47  
   hydration, 751  
   hypopituitarism, 746–47  
   incidence and prevalence, 743t24.1  
   individual variation, 746

## Index

- fatigue after concussion  
 (*cont.*)  
 management, 748–53  
 management recommendations, 753–54  
 medication review, 753  
 mental fatigue, 744–46  
 neuroendocrine assessment, 748  
 neuroendocrine  
 considerations, 746–47  
 neurostimulants, 753  
 pharmacological  
 approach, 752–53  
 phenotypic fatigue  
 measurement, 746  
 sleep hygiene, 750–51  
 substance use, 751  
 Fatigue Impact Scale (FIS), 748, 748t24.2  
 fatigue management, 794–95  
 Fatigue Severity Scale (FSS), 744, 748, 748t24.2, 753  
 FBPK5 gene, 392  
 fear conditioning  
 role of the hippocampus, 392  
 Federal Interagency TBI Research (FITBIR) informatics system, 696–710  
 female sex  
 risk factor for poor outcomes of CBI, 337–43  
 FIFA Medical Assessment and Research Centre, 82  
 finite element modeling (FEM) of CBI, 300–2  
 FLAIR, 264t6.1  
 fluid dysregulation after TBI, 751  
 Fluid Percussion Injury Model (FPI), 160–61, 162–64  
 fluoxetine, 389  
 Foley, Joe, 24  
 football (American style)  
 CBIs classified as  
 non-concussions, 121–23  
 concussion reporting methods, 119–23  
 concussion risk, 119–23  
*See also* sport-related concussion, 123  
 force of the CBI impact  
 predictive value for outcomes, 299–302  
 Ford, Henry, 50  
 fractional anisotropy (FA), 266–70  
 Freud, Anna, 403  
 Freud, Sigmund, 11, 52, 54, 402, 403  
 frontal lobotomy, 403  
 frontotemporal dementia (FTD), 171  
 frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U), 537  
 Functional Independence Measures (FIM), 289  
 functional MRI (fMRI), 76, 678–79  
 advantages and limitations in TBI, 724  
 applications in mTBI, 716  
 BOLD response, 716–17  
 clinical challenges in fMRI research following TBI, 722–23  
 effects of TBI on the fMRI response, 716–17  
 emotional sequelae following TBI, 723  
 impetus for developing objective psychiatric metrics, 723  
 methodological and analytical challenges in TBI studies, 717–18  
 neurovascular  
 coupling, 716–17  
 physiology of the fMRI response, 716–17  
 recognition the CBI can cause brain change, 716  
 review of current findings from the literature, 718–22  
 studying chronic effects of brain injury, 559–60  
 functional neuroimaging  
 APOE  $\epsilon$ 4 carriers with TBI, 565–66  
 multiple concussions, 560–63  
 subconcussive head trauma, 564–65  
 gait measures, 677  
 Galen, 39, 289, 291, 360, 501  
 Galileo Galilei, 33  
 Gall, Franz Joseph, 292  
 Galton, Francis, 16  
 Galveston Orientation and Amnesia Test (GOAT), 96  
 Gama, Jean-Pierre, 45, 262  
 Gandhi, Mahatma, 501  
 Gap43 gene, 145  
 Garrod, Archibald E., 210, 288, 291, 298, 358, 544  
 gene-environment interactions, 306  
 gene expression  
 after CBI, 68–72  
 three-dimensional patterns, 307–10  
 gene-gene interactions, 306  
 gene modulation after concussion, 144–45  
 genetic factors  
 gene variants which appear to influence TBI outcome, 310–11  
 risk factors for mood disorders associated with TBI, 387  
 risk factors for PTSD, 392  
 risk of post-concussive PTSD-type distress, 461–63  
 role in CBI outcome variations, 305–18  
 search for genes linked to neurobiological traits, 311–12  
 stress vulnerability genes, 312–13  
 genetic variation  
 influence on size and shape of brain parts, 297  
 genome-wide association studies (GWAS), 311  
 GFAP biomarker, 640, 641  
 Gilberti, Vincent, 3  
 Giza, Christopher, 94  
 Glasgow Coma Scale (GCS), 96, 648  
 applications and limitations, 408  
 measure of  
 awakeness, 291–92  
 misinterpretation of scores, 138  
 not a measure of injury severity, 291–92  
 Glasgow Outcome Scale (GOS), 78  
 Glasgow Outcome Scale-Extended (GOSE), 217  
 Glasgow Outcome Score (GOS), 289  
 Global Fatigue Index (GFI), 748  
 globus pallidus, 388  
 glucose metabolism  
 derangement following CBI, 140  
 GluR2 gene, 145  
 glutamate, 179, 762  
 binding to ionic channels in CBI, 139  
 glutamate and glutamine (Glx)  
 MR spectroscopy, 271  
 glutathione  
 MR spectroscopy, 273  
 glycolysis  
 temporary increase following CBI, 140  
 Golden, C.J., 406  
 Goldstein, Kurt, 56, 58  
 Golgi, Camillo, 45–46  
 gonadotrophins, 767  
 deficiency symptoms, 768t26.1  
 good-old-days bias in symptom reporting, 346  
 Grin2d gene, 145  
 growth hormone, 767  
 deficiency after  
 concussion, 746–47  
 deficiency symptoms, 768t26.1  
 replacement therapy, 776  
 guiding principles for clinical practice, 793–96  
 acute and sub-acute management, 793–94  
 balancing rest versus activity, 794–95  
 fatigue management, 794–95  
 neurobiology as a guiding principle, 794  
 post-acute assessment, 794  
 prioritizing and treating comorbidities, 795  
 tailoring subsequent treatment to the individual, 795–96  
 Gulf War Syndrome, 684  
 Guthrie, G.J., 44  
 gyrus rectus, 388  
 Haddon Matrix, 210, 358–60, 430, 432, 446  
 hallucinations  
 related to sleep disorders, 760  
 Halstead, W.C., 406  
 Halstead-Reitan Neuropsychological Battery, 406–7  
 Hartmann, Heinz, 403  
 Head Impact Telemetry System, 300  
 headache variants, 730–35  
 cervicogenic  
 headache, 731–32  
 craniomandibular  
 syndrome, 731  
 dehydration headache, 731  
 dysautonomic headaches, 735  
 effort-induced headache, 731  
 exertional headache, 730–31  
 headache associated with  
 arterial dissection, 735  
 medication induced  
 headache, 735  
 medication overuse headache, 734, 735  
 migraine headaches, 733–35  
 musculoskeletal headache, 731  
 neuritic and neuralgic head pain, 732  
 occipital neuralgia, 732  
 paroxysmal hemicrania, 735  
 post-traumatic cluster  
 headache, 735  
 post-traumatic  
 migraine, 733–35  
 rebound headache, 734  
 temporomandibular  
 joint dysfunction (TMJD), 731  
 tension-type headache, 732–33  
 third occipital nerve  
 headache, 732  
 trauma-triggered  
 migraine, 734–35  
*See also* post-concussive headache, 735  
 HeadMinder Concussion Resolution Index, 675  
 Health Related Quality of Life (HRQOL), 216  
 Hebb, Donald, 403  
 hemosiderin detection  
 neuroimaging, 269–75  
 Hewett, P., 44  
 hippocampus, 388

- functions, 179  
 neurogenesis during sleep, 756  
 neurogenesis in adults, 173  
 role in fear conditioning, 392  
 volume reduction in PTSD patients, 392  
 vulnerability to concussion, 179–82
- Hippocrates, 33, 360  
 Hippocratic view of concussion, 36–38
- histamine, 757
- histopathology versus imaging, 263
- historical views of concussion, 36  
 1600–1700, 40–42  
 1700–1800, 42–43  
 1800–1900, 44–45  
 1900–1925, 50–53  
 1930 and beyond, 55–56  
 Ancient Egypt, 38  
 arrival of the microscope, 45–47  
 association with ‘mild’, 37  
 attorneys and the invention of mild TBI, 54  
 beyond the Hippocratics, 38–40  
 blast injury victims, 53  
 casualties of World War I, 50–52  
 Cellini, Benevenuto, 39  
 clarity at the outset of the 20th century, 49–50  
*commotio cerebri* concept, 39  
 controversy over the accepted benignity of concussion, 56–58  
 da Carpi, Berengario, 39–38  
 early animal experiments, 45  
 Edwin Smith Surgical Papyrus, 38  
 effect of workers’ injury compensation schemes, 47–49  
 expansion of payments for personal injury, 51–52  
 experimental concussion, 45  
 fallacy of benignity, 53–54  
 Hippocratic view, 36–38  
 Homer’s *Iliad*, 38–39  
 hysteria, 47–49  
 illogical approach to categorization, 37  
 influence of increasing litigation, 54–55  
 means to avoid injury compensation liability, 52–53  
 narrowing of the definition, 37  
 Paré, Ambroise, 39–40  
 popularity of psychological explanations, 52–53  
 pressure to rate the severity of concussion, 54–55  
 progress in recognition of structural change, 55
- reasons for inconsistent use of the term ‘concussion’, 54–55  
 shell shock, 50–52, 53  
 tendency to view as a single disorder, 37  
 translation by Francis Adams, 36–37  
 translation by William Caxton, 37  
 traumatic neurosis, 47–49
- history of prior TBI influence on later CBI outcome, 329–35  
 Hitler, Adolf, 403  
 Holbourn, A.H.S., 59–60, 262  
 homeostatic sleep drive, 757  
 Homer’s *Iliad*, 38–39  
 Hooke, Robert, 45  
 hormones risk factors for PTSD, 391–92  
 Hovda, David, 94
- human brain Brodmann’s areas, 292–93  
 diaschisis, 295  
 differences in MZ twins, 294–95  
 evidence against localizationism, 294–99  
 gene-mediated variation in size and shape of brain parts, 297  
 genetic variation in brain structure, 312  
 history of localizationism, 292–93  
 variations in, 292
- human concussion debate, 205–6  
 accurate baseline data is rarely available, 210  
 clinicians encounter non-representative samples of CBI survivors, 208  
 Dear Leader Experiment, 214–16  
 detecting persistent change requires effort, 210–12  
 difficulty of determining clinico pathological correlations, 209  
 ethical restraints on research, 213–16  
 individual variation not considered in Western nosology, 210  
 lack of a systematic review of human outcome data, 218  
 limitations of animal experiments, 210  
 no single method assesses outcome with reliability and ecological validity, 216–18  
 opinions harden in the face of uncertainty, 213  
 patient-generated barriers to understanding, 212
- persistent belief in mind/brain dualism, 209  
 post-concussion syndrome, 210  
 reasons why there is still a debate, 208–18  
 recovery is not confirmable, 212  
 resistance to the idea that brains mediate mental functions, 209  
 socioeconomic pressures on patients with persistent complaints, 212–13  
 three-month recovery myth, 210–12  
 typical post-CBI problems, 207–8  
 Western medical approach to concussion assessment, 210–12
- Human Connectome Project, 264–65, 297–99
- human studies review, 218  
 approaches to analysing the results, 234–41  
 challenge of comparing study results, 234–41  
 conclusions, 249–50  
 effect of controlling for pre-morbid status, 241  
 estimating the prevalence of persistent neurobehavioral problems, 248  
 features of the Tables of results, 221–34  
 group averages hide individual variations, 220–21  
 normal test scores do not exclude the possibility of brain injury, 221  
 quantitative approach when meta-analysis is not possible, 248  
 recovery may be behavioral adaptation, 248–49  
 studies included in the results, 242  
 study by Sven J. Dencker (Sweden, 1954), 220–21  
 study selection criteria, 219–20  
 Table 3 (studies without controls), 242  
 Table 4 (studies with controls), 242–44  
 Table 5 (medium- to long-term studies with healthy or ill controls), 244–47  
 unreliability of predictions of long-term outcome, 221  
 weaknesses in study designs, 249
- Hunter, John, 44  
 hydration in CBI patients, 751  
 hypersomnia, 758
- hypocretin receptor blockers, 763–64  
 hypocretin-1, 760  
 hypopituitarism after concussion, 746–47  
 hypothalamic-pituitary-adrenal (HPA) axis changes in PTSD, 392  
 effect of childhood abuse, 391  
 hypothalamus, 388, 392  
 interaction with the anterior pituitary, 767  
 production of orexin, 760  
 hypoxic/ischemic theory of CBI, 262  
 hysteria, 47–49  
 explanation given for female CBI outcomes, 338
- ICD diagnostic criteria, 95
- ice hockey concussion risk, 123–24
- IL-1b gene, 144
- imaginary/intentional dichotomy of symptoms, 13–14
- Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), 656, 675
- Impact Acceleration Injury Model (IAI), 160–61
- Impact of Event Scale, 459
- incomplete sentences tests, 403
- individualized neuroimaging biomarker detection, 274–77
- inertial forces in CBI, 139
- inflammation role in CBI pathophysiology, 66–68
- inflammatory hypothesis of tauopathy development, 536
- insula, 388
- interleukin-1 (IL-1), 762  
 interleukin-4 (IL-4), 762  
 interleukin-6 (IL-6), 762
- intermittent explosive disorder (IED) following TBI, 444
- International Collaboration on MTBI Prognosis, 384
- International Ice Hockey Federation (IIHF), 82
- International Mission on Prognosis Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) initiative, 7
- International Olympic Committee (IOC) Medical Commission, 82
- inter-subject variability, 296  
 intra-subject variability, 296  
 IQ testing, 403

## Index

- irritability after trauma, 385–86  
 assessment in concussion  
   patients, 385  
 epidemiology, 446  
 features of, 385  
 following TBI, 444  
 incidence, 385  
 personality change after TBI, 385  
 progression to aggressive  
   behavior, 385  
 treatments, 385–86  
 Irritability Questionnaire, 385
- Jackson, Hughlings, 402  
 James, William, 499, 500  
 Jansen, Zacharias, 45  
 Johnson, Ted, 119
- kainate receptor binding in  
   CBI, 139  
 Kaplan, Michael, 171–72, 173  
 karate  
   concussion risk, 124  
 Keck, Michael  
   CTE case history, 530  
 Kennard, Margaret, 654  
 King-Devick test  
   (K-D), 657–58  
 knowledge about CBI  
   current controversies, 1–2  
 knowledge about CBI,  
   barriers to, 2  
   author bias, 22–24  
   insufficient empirical  
     investigation, 3–10  
   lack of a meaningful outcome  
     measure, 11  
   levels of suspicion of  
     malingering or  
     fraud, 24–25  
   misplaced faith in a  
     dated trichotomy of  
     symptoms, 11–14  
   misplaced faith in  
     authority, 14  
   misplaced faith in cognitive  
     testing, 17–22  
   misplaced faith in consensus  
     groups, 14–16  
   misplaced faith in flawed  
     modes of enquiry, 14–22  
   pressures to minimize  
     reporting of concussion  
     and symptoms, 25–26  
 Korean War  
   post-concussion syndrome or  
     neurosis, 684  
 Krause, Feodor, 293  
 Krebs' cycle, 141  
 Kris, Ernst, 403
- lacrosse  
   concussion risk, 124–25  
 lamotrigine, 390  
 Lashley, Karl Spencer, 401–2  
 late effects of CBI  
   Auguste Deter case of  
     Alzheimer's disease, 501  
   case of Chani, 496–97  
   categorization of  
     phenomena, 499–501  
   challenges of  
     diagnosis, 496–97  
   challenges to  
     traditional disease  
     categories, 499–501  
   classification of differences by  
     degree or by kind, 501–2  
   defining aging, 502–7  
   defining Alzheimer's  
     disease, 512–26  
   defining chronic traumatic  
     encephalopathy  
     (CTE), 526–40  
   defining dementia, 509–12  
   defining neurodegeneration,  
     507–9  
   dementia risk, 497–98  
   distinguishing between  
     normal and  
     abnormal, 499–501  
   distinguishing between same  
     and different, 499–501  
   efforts to mitigate deleterious  
     effects, 543–44  
   future developments, 544  
   pediatric concussion, 665–66  
   possible link between TBI and  
     later MS, 538–40  
   problems with the DSM  
     system, 502  
   research studies  
     needed, 542–43  
   risk of, 497–98  
   role of tau oligomers, 543–44  
   summary of take-home  
     messages, 538  
   time-passing-related life-  
     history concept of  
     aging, 505–7  
   towards a rational  
     neurological  
     nosology, 540–42  
   unresolved concepts and  
     terminology, 498–99  
 late effects of TBI  
   functional neuroimaging  
     studies, 557–59  
 Late Effects of Traumatic Brain  
   Injury study  
   methodological issues, 800–1  
 lateral orbitofrontal circuit  
   (LOPFC)  
   role in post-TBI mood  
     disorders, 388  
 legal cases  
   British system for expert  
     witnesses, 804  
   collective bargaining approach  
     for expert witnesses, 806  
   expert shopping by parties to  
     litigation, 804–5  
   expert witnesses under the  
     U.S. system, 804–5  
   history of use of expert  
     witnesses, 803–4  
   pressures on expert  
     witnesses, 803  
   problem of biased expert  
     witnesses in the U.S., 805  
   voluntary duty clause for  
     expert witnesses, 805–6  
 legal implication of sport-related  
   concussion, 127–28  
 Lethality of Suicide Attempts  
   Rating Scale, 436  
 leucotomy, 403  
 Lezak, Muriel D, 407  
 Life Events Checklist, 687  
 Life Span Study (LSS) of atomic  
   bomb survivors, 617  
 linear acceleration in CBI, 139  
 linear no-threshold (LNT)  
   model, 617  
 lithium carbonate, 390  
 Littré, A., 42  
 localizationism  
   history of, 292–93  
 Lowenstein, Rudolph, 403  
 Luria, Alexander, 402, 404  
 Luria-Nebraska  
   Neuropsychological  
   Battery, 406–7  
 Lyell, Charles, 305
- Maddock's questions, 648  
 malingering, 51–52, 55, 346, 347,  
   353, 354  
   APA diagnostic criteria, 346  
   levels of suspicion among  
     doctors, 24–25  
 marijuana  
   effects on post-concussive  
     aggression, 451–52  
 Marshall, Lawrence F., 24  
 martial arts  
   concussion risk, 124  
 Martland, Harrison S., 555  
 Massaquoi, Steve, 352  
 maximal axonal strain  
   predictive value for CBI  
     outcome, 302  
 mechanical forces involved in  
   CBI, 139  
 medication induced  
   headache, 735  
 medication overuse headache,  
   734, 735  
 MEG (magnetoence-  
   phalography), 274–77  
 melatonin, 757  
   disruption after CBI, 762  
 melatonin receptors  
   single nucleotide  
     polymorphisms  
     (SNPs), 762  
 memory loss  
   myth of missing traumatic  
     memory, 106–7  
 Mendelev, Dmitri, 500  
 Mesulam, M.M., 296  
 meta-analyses of concussion  
   studies, 18–21  
 methylphenidate, 385, 389, 753
- Meyers, Charles, 104  
 Mickle, William, 422  
 microscope  
   influence on investigation of  
     concussion, 45–47  
 microscopy  
   findings affected by  
     different staining  
     techniques, 176–78  
   limits in discovery of  
     post-concussive brain  
     change, 176–78  
 Migraine Disability  
   Assessment (MIDAS)  
   questionnaire, 738  
 migraine headaches, 733–35  
 mild  
   misleading use in relation to  
     TBI, 138  
   origins of association with  
     concussion, 37  
   questioning its application to  
     TBI/CBI, 77–78  
 mild TBI (mTBI)  
   invention of, 54  
   World Health Organization  
     definition, 84  
 Miles, Alexander, 46–47  
 Military Acute Concussion  
   Evaluation (MACE), 673  
 military concussion  
   epidemiology, 104–8  
   association between  
     concussion and  
     PTSD, 106  
   incidence of TBI/CBI in  
     recent conflicts, 105–6  
   myth of missing traumatic  
     memory, 106–7  
   rates of PTSD in those with  
     CBI, 107–8  
   reasons for the CBI/PTSD  
     link, 108  
   shell shock, 104  
 military personnel  
   assessing current  
     symptoms and  
     functioning, 687–89  
   assessment approaches for  
     PCS/PPCS, 689  
   assessment approaches for  
     PTSD, 689  
   biopsychosocial  
     conceptualization of  
     CBI, 684–85  
   comorbidities of  
     deployment-related  
     TBI, 685–86  
   comorbidity of CBI and  
     PTSD, 683  
   considerations for  
     treatment and  
     rehabilitation, 689–90  
   context and motivational  
     factors influencing  
     symptom report, 688–89  
   depression comorbid with TBI  
     and PTSD, 685



- diagnostic challenges of post-deployment polytrauma, 683t20.1
- diagnostic considerations and challenges for CBI and psychological trauma, 686–89
- distinguishing mild TBI from PTSD, 390
- establishing injury events and psychological trauma exposure, 686–87
- etiologies of contemporary polytrauma, 684–85
- Gulf War Syndrome, 684
- history of deployment-related polytrauma health concerns, 683–84
- incidence of chronic pain, 686
- incidence of post-deployment CBI, 683
- incidence of PTSD, 683
- incidence of PTSD associated with TBI, 390
- overlapping symptoms across disorders, 687–88
- physical comorbidities with TBI, 686
- polytrauma triad (pain, PPCS and PTSD), 686
- post-concussion syndrome or neurosis (World War II, Korean War), 684
- Post-Deployment Health Assessment, 688
- Post-Deployment Health Re-Assessment, 688
- post-TBI substance abuse, 685–86
- PTSD comorbid with TBI, 685
- research into mTBI and PTSD, 7
- results of head injuries in 20th-century conflicts, 403–4
- risk factors for persistent post-concussive symptoms, 684–85
- shell shock (World War I), 684
- structural brain changes in TBI and PTSD patients, 393
- Mill, John Stuart, 499, 500
- Miller, Henry, 351–53
- Miller, Timothy, 544
- Mini-Mental State examination, 511
- mitochondria, 93
- calcium overloading in CBI, 139
- mixed, multidisciplinary interventions
- systematic review of research, 790–91
- modafinil, 753
- Modified Fatigue Impact Scale (MFIS), 748, 748t24.2
- monoamine oxidase inhibitors (MAOIs), 389
- Montreal Cognitive Assessment (MoCA), 511
- mood disorders
- barriers to accurate incidence and prevalence accounting after concussion, 387
- classification systems, 386
- clinical presentation and diagnosis, 386
- comorbidities, 386
- diagnostic criteria, 386
- epidemiology of traumatic emotional change, 387–88
- functional impact, 386
- genetic risk factors after TBI, 387
- pathophysiology of post-TBI mood disorders, 388–89
- possible causal factors, 386
- psychosocial risk factors before and after TBI, 387
- role of prefrontal circuits, 388–89
- role of the lateral orbitofrontal circuit (LOPFC), 388
- role of the orbital-ventromedial prefrontal circuit (OVMPFC), 388
- treatment, 389–90
- with depressive features, 386, 387, 389
- with manic, hypomanic, and mixed features, 387–88, 389–90
- with manic, hypomanic, or mixed features, 386
- mood stabilizers, 389–90
- Morris, John, 512
- Morris Water Maze, 166
- Mott, Frederick, 56, 57, 104
- MRS (MR spectroscopy), 266, 271–76
- choline, 271
- creatine, 273
- glutamate and glutamine (Glx), 271
- glutathione, 273
- myo-inositol, 271–73
- NAA (N-acetyl aspartate), 271
- studies of multiple concussions, 566–67
- MTHFR gene polymorphisms, 387, 434
- Multidimensional Assessment of Fatigue (MAF), 748t24.2
- Multidimensional Fatigue Inventory (MFI), 748
- Multi-dimensional Fatigue Severity Scale, 744
- multifocal effects of CBI, 34
- multi-modal concussion assessment battery, 677
- multiple sclerosis (MS)
- adolescent TBI as possible trigger for later MS, 538–40
- multiple sleep latency test (MSLT), 758, 762
- Munro, D., 56
- musculoskeletal headache, 731
- myelin basic protein (MBP) biomarker, 641
- myo-inositol
- MR spectroscopy, 271–73
- NAA (N-acetyl aspartate), 74–75
- MR spectroscopy, 271
- role in CBI pathophysiology, 140–43
- narcolepsy, 760
- NAT8L (N-acetyltransferase 8-like), 140, 141
- NAT8L gene, 141
- National Ambulatory Medical Care Survey (NAMCS), 98
- National Athletic Trainers' Association
- definition of concussion, 82
- National Center for PTSD, 391
- National Collegiate Athletic Association (NCAA)
- Injury Surveillance Program, 112, 113
- National Electronic Injury Surveillance System-All Injury Program, 646
- National Hospital Ambulatory Medical Care Survey (NHAMCS), 98
- National Hospital Discharge Survey (NHDS), 98
- National Institute for Health and Clinical Excellence (NICE)
- guideline on CT scan after concussion, 603–5
- National Institute of Neurological Disorders and Stroke (NINDS), 3, 694
- National Institute on Disability and Rehabilitation Research (NIDRR), 694
- National Institutes of Health Toolbox, 290
- National Taiwan University Irritability Scale, 385
- natural kinds, 499, 501
- Natural Setting Behavior Management, 449
- near-infrared spectroscopy, 277
- neprilysin polymorphisms, 168
- network analyses
- integrating structural and functional neuroimaging, 274
- neuralgic head pain, 732
- neuritic head pain, 732
- Neurobehavioral Symptom Inventory, 385, 459, 688, 689
- neuroendocrine dysfunction
- pituitary gland structure and function, 767
- neurocircuits
- disruption in comorbid TBI and PTSD, 463–65
- neurodegeneration
- in animal models of concussion, 168–71
- association with CBI, 72–77
- classification of TBI-induced disorders, 578–79
- defining, 507–9
- distinguishing normal and abnormal changes, 508–9
- grey matter volume reduction and functional decline, 509
- grey matter volume reduction in pregnancy, 509
- lack of a shared definition, 507
- neuronal loss and functional decline, 509
- no-new-neurons hypothesis, 509
- potential candidates for defining elements, 507–8
- TBI risk factor, 573
- neuroendocrine dysfunction
- clinical consequences of hypopituitarism, 774
- effects of concussion in children and adolescents, 773–72
- future research, 776
- natural history of hypopituitarism, 773–74
- pathophysiology of pituitary trauma injury, 768
- pituitary hormone deficiency after CBI, 767
- pituitary hormone replacement therapies, 775–76
- posterior pituitary (neurohypophysis) dysfunction, 773
- prevalence of anterior pituitary dysfunction after TBI, 768–72
- prevalence of post-traumatic hypopituitarism, 767–68
- repetitive concussion in adults, 772
- screening protocols, 774–75
- neurofilament heavy (NF-H) biomarker, 640, 641
- neurofilament light (NF-L) biomarker, 639, 640
- neurogenesis
- evidence in adults, 171–73
- the 'no new neurons' dogma for adults, 171–73
- role in post-CBI recovery, 173–76
- neuroglobin
- role in CBI, 139–40
- neuroimaging of CBI
- APOE  $\epsilon$ 4 carriers with TBI, 567–68

## Index

- neuroimaging of CBI (*cont.*)  
 asking the right questions, 278–79  
 asymptomatic persistent brain change, 556  
 candidate neuroimaging biomarkers, 263–77  
 delayed onset persistent symptoms, 556–57  
 DTI (diffusion tensor imaging), 264, 265–66, 267–75  
 finite element (FE) modeling, 266  
 FLAIR, 264t6.1  
 future developments in biomarkers, 278–79  
 hemosiderin detection, 269–75  
 heterogeneity of late effects of repeated CBI, 629–30  
 histopathology versus imaging, 263  
 Human Connectome Project, 264–65  
 hypoxic/ischemic theory of CBI, 262  
 improvements in technology, 263  
 individualized neuroimaging biomarker detection, 274–77  
 interest in the late effects of CBI, 555–56  
 levels of structure within the nervous system, 265–67  
 limitations of CT (computed tomography), 262–63  
 MEG (magnetoencephalography), 274–77  
 MRS (MR spectroscopy), 266, 271–76  
 MRS studies of multiple concussions, 566–67  
 near-infrared spectroscopy, 277  
 need for a multi-modal approach, 568  
 need for biomarkers of brain change, 261–62  
 network analyses that integrate structural and functional neuroimaging, 274  
 network theory of CBI outcomes, 556–57  
 neurobiological significance of observed changes, 266–67  
 neurometabolic cascade, 263  
 new clinical paradigm of CBI, 277–78  
 pediatric concussion, 658–59  
 PET (positron emission tomography), 277  
 quantitative MRI, 264t6.1  
 repeated subconcussive trauma, 567  
 review of studies of late effects of TBI, 557–59  
 shear injury in TBI, 262–63  
 situation before neuroimaging was available, 260–61  
 SPECT (single photon emission computed tomography), 277  
 structural MRI, 263–75  
 structural neuroimaging, 263  
 SWI (susceptibility weighted imaging), 264t6.1  
 symptomatic persistent brain change, 556–57  
 white matter damage in TBI, 262–63  
 neuroinflammation CSF biomarkers, 640  
 neurologists ability to care for concussion survivors, 416  
 neurology anti-intellectualism in medicine, 803  
 psychological traits of neurologists, 801–2  
 resistance to a logical nosology, 801–2  
 neurometabolic cascade, 63–66, 94, 263, 762  
 neuronal injury CSF biomarkers, 640  
 neurophysiological assessment tools, 677–79  
 Neuropsychiatric Inventory (NPI), 445  
 neuropsychiatrists ability to care for concussion survivors, 416  
 Neuropsychiatry Inventory (NPI), 385  
 neuropsychological assessment need for biomarkers of brain change, 261–62  
 three month myth of CBI recovery, 260–61  
 neuropsychological testing, 675–77  
 limitations, 124  
 neuropsychologists ability to care for concussion survivors, 417–18  
 neuropsychology acknowledgment of the limitations of the discipline, 413–14  
 beginnings of professional neuropsychology, 403–4  
 behavioral observations during psychological testing, 414–15  
 care for the persistently distressed CBI patient, 415–18  
 changing views on the use of psychological testing, 412  
 comparison of brain imaging and psychological testing, 404  
 consequences of World War II, 402–3  
 damage versus dysfunction debate, 407  
 development of batteries of tests, 406–7  
 development of testing methods, 403–4  
 developments using virtual reality, 414  
 distinction between psychiatric disorders and brain disorders, 402–3  
 early controversies, 404–5  
 ethical issues, 413–14  
 forensic role and ethics, 413–14  
 future directions of the discipline, 414  
 historical development of the discipline, 401–12  
 implications of recognition of persistent distress in CBI, 399  
 influence of psychoanalysis, 403  
 limitations of psychological testing in concussion, 408–11  
 limitations of psychological testing in sports-related brain injury, 411–12  
 limitations of testing and imaging, 407–8  
 new approaches to administering stimuli, 414  
 observing responses, 414–15  
 prioritizing emotions, 415  
 psychological testing to identify brain damage, 402–3  
 question of validity of testing methods, 403–7  
 reinventing the field, 399–401  
 sports neuropsychology, 411–12  
 support for psychological testing in sports-related concussion, 411–12  
 timing of testing and imaging in CBI, 407–8  
 treatment and the healthcare system, 415–18  
 what tests to administer, 412–13  
 neurostimulants, 753  
 neurovascular coupling, 716–17  
 New Orleans Criteria (NOC), 600, 600t15.3  
 New South Wales (NSW) protocol for CT scan after concussion, 601–2  
 nitric oxide (NO) synthase activation in CBI, 139  
 nitrosative stress caused by CBI, 139–40  
 nitroxyl, 139  
 NMDA receptor binding in CBI, 139  
 non-cognitive behavioral complications of CBI, 384  
 nosology conservative approach in neurology, 801–2  
 illogical approach to categorization of concussion, 37  
 lack of consideration of individual variation, 210  
 lack of valid criteria for psychiatric conditions, 346  
 limitations which delay understanding of CBI, 802–3  
 towards a rational neurological nosology, 540–42  
 Nottebohm, Fernando, 173  
 NPY gene, 392  
 Nr4a1 gene, 145  
 NSE biomarker, 640, 641, 642  
 nuclear factor kappa B (NFkB), 762  
 nucleus of the solitary tract, 392  
 obstructive sleep apnea, 758–60  
 occipital neuralgia, 732  
 Ohio State University TBI Identification Method, 687  
 olanzapine, 390  
 oligodendrocytes, 141  
 Ontario Neurotrauma Foundation (ONF) guidelines on CT scan after concussion, 602  
 Oppenheimer, D.R., 66–67  
 orbital-ventromedial prefrontal circuit (OVMPFC) role in post-TBI mood disorders, 388  
 orbitofrontal cortex, 388  
 orexin, 757, 760  
 disruption after CBI, 762  
 orexin receptor blockers, 763–64  
 organic/psychological dichotomy of symptoms, 12–13  
 non-existence of, 320–28  
 Osler, William, 210, 291  
 Osnato, Michael, 3  
 outcome measures. *See* Common Data Elements (CDEs) project  
 outcomes of CBI age-related risk for poor outcomes, 343–45  
 APOE genotype risks to children, 315–18

- arguments for and against  
 APOE genotype  
 testing, 313–18
- bad outcome risk factors  
 most commonly cited in  
 studies, 318–19
- barriers to understanding  
 persistent post-CBI  
 symptoms, 345–48
- brain individuality  
 in structure and  
 function, 292–99
- brain injury is not a  
 disease, 290–91
- brain-mind reciprocating  
 trauma, 360
- brain reserve hypothesis  
 of social  
 disadvantage, 356–57
- changing conceptions of  
 disease, 290–91
- compensation issues, 348–55
- difference between cause and  
 risk factor, 291
- different causal pathways  
 to post-CBI  
 symptoms, 328–29
- drama of attribution, 348,  
 357–58
- duration of impact, 301–2
- effects of axonal stretch on A $\beta$   
 and tau, 331–34
- emergence of PTSD, 303
- epigenetic influences, 306–7
- evidence against  
 localizationism, 294–99
- failure to return to work, 356
- female sex risk factor for poor  
 outcomes, 337–43
- finite element modeling  
 (FEM) of CBI, 300–2
- functional outcome  
 measures, 289
- gene-environment  
 interactions, 306
- gene-gene interactions, 306
- gene variants which  
 appear to influence  
 outcome, 310–11
- genetic variation in brain  
 structure, 312
- Haddon Matrix, 358–60
- Head Impact Telemetry  
 System, 300
- heterogeneity of  
 outcomes, 285–86
- history of  
 localizationism, 292–93
- how brainstuff produces  
 the different CBI  
 symptoms, 328–29
- idealized and actual  
 recovery trajectories  
 compared, 285–86
- influence of APOE  
 genotype, 313
- influence of prior  
 TBI(s), 329–35
- influence of premorbid  
 neuropsychiatric  
 problems, 335–37
- inheritance of acquired  
 changes in DNA  
 (epigenetics), 306–7
- interactions between the  
 force and individual  
 biology, 328–29
- interplay of multiple  
 factors, 358–60
- lack of a meaningful outcome  
 measure, 11
- lack of valid psychiatric  
 nosology, 346
- measures of outcomes, 289–90
- non-existence of the organic/  
 psychological dichotomy  
 of symptoms, 328
- non-linear course of  
 recovery, 302–5
- number of alternative  
 pathways, 290
- point-of-no-return  
 theory, 334–35
- post-concussion syndrome, 292
- predictive value of maximal  
 axonal strain, 302
- predictive value of the force of  
 the impact, 299–302
- problem of explaining why  
 outcomes vary, 286–87
- problems with psychological  
 explanations, 345–48
- professional concussion  
 deniers (PCDs), 346–47
- recognition that there is no  
 single outcome, 288–89
- relative change from  
 baseline, 289–90
- relative change from  
 baseline on multiple  
 measures, 290
- response bias in symptom  
 reporting, 345–55
- risk factors for persistent  
 problems (systematic  
 review), 319–20
- risk factors for worse  
 outcome, 291–92
- risk of later Alzheimer's  
 disease, 329–35
- risk of later chronic traumatic  
 encephalopathy  
 (CTE), 329–35
- similar forces are followed by  
 different effects, 290
- social disadvantage risk  
 factor for poor  
 outcome, 355–57
- straw man issue of mind/body  
 dualism, 328
- stress vulnerability  
 genes, 312–13
- symptoms at different  
 follow-up times, 302–5
- three-dimensional patterns of  
 gene expression, 307–10
- threshold between injury and  
 non-injury, 334–35
- transcriptomics, 305–10
- uniqueness of every  
 concussion, 360
- up- and down-regulation  
 of genes in response to  
 CBI, 305–10
- variance related to genetic  
 factors, 305–18
- variance related to time after  
 impact, 302–5
- output brainstem nuclei, 392
- oxcarbazepine, 390
- oxidative stress caused by CBI, 139
- OXTR gene, 306
- oxytocin, 767
- Paaw, Peter, 40
- Page, James D., 403
- Pain Disability Questionnaire  
 (PDQ), 738
- Paré, Ambroise, 39–40
- Parker, Harry L., 555
- paroxetine, 389
- paroxysmal hemicrania, 735
- pathological change  
 definition, 540
- pathophysiology of CBI  
 altered protein  
 degradation, 72–77
- ATP/ADP ratio, 140, 141, 142,  
 145, 146
- biological definition of  
 CBI, 58–59
- clinical implications, 147–49
- competition between  
 degenerative  
 and regenerative  
 pathways, 144–45
- complexity and individual  
 variation, 68–72
- consequences of misleading  
 terminology and  
 definitions, 138
- consistent findings, 59
- contact forces, 139
- defining CBI as a disease  
 or a biological  
 problem, 77
- defining recovery, 78–79
- derangement of glucose  
 metabolism, 140
- external force and  
 the metabolic  
 cascade, 138–40
- from biomechanical  
 to biochemical  
 effects, 138–40
- gene expression after  
 CBI, 68–72
- gene modulation after  
 concussion, 144–45
- goal of reducing the toll of  
 TBI/CBI, 84
- imbalance between ATP  
 consumption and  
 production, 140
- inertial (acceleration)  
 forces, 139
- inflammatory response, 66–68
- ionic cellular  
 derangement, 139
- key issues for future  
 studies, 149
- linear acceleration, 139
- measuring and  
 monitoring post-  
 concussive metabolic  
 imbalance, 140–43
- mechanical forces  
 involved, 139
- misleading use of the term  
 'mild', 77–78, 138
- mitochondrial calcium  
 overloading, 139
- neurodegeneration, 72–77
- neurometabolic  
 cascade, 63–66
- nitrosative stress, 139–40
- oxidative stress, 139
- possible causes of CBI  
 symptoms, 138
- post-concussive  
 melee, 144–45
- potential public health impact  
 of CBI, 138
- proteolysis of voltage-gated  
 sodium channels, 139
- release of  
 neurotransmitters, 139
- role of acetyl-CoA, 140, 141,  
 143
- role of N-acetyl aspartate  
 (NAA), 140–43
- role of neuroglobin, 139–40
- rotational acceleration, 139
- second impact  
 syndrome, 145–47
- shear forces, 139
- spectrum of axonal  
 injuries, 59–63
- stretch or strain forces, 139
- temporary increase in  
 glycolysis, 140
- toxic accumulation, 72–77
- transfer of mechanical forces  
 to the brain, 139–40
- vulnerability of the post-  
 concussive brain, 145–47
- window of metabolic brain  
 vulnerability, 141–42
- patient-generated barriers  
 to understanding  
 concussion, 212
- Patient Health  
 Questionnaire-9, 436
- patients  
 anosognosia, 216
- pediatric concussion  
 acute symptom onset and  
 recovery, 648–49
- benefits of physical activity for  
 the brain, 666
- brain changes in children with  
 no symptoms, 646



## Index

- pediatric concussion (*cont.*)  
 concussion safety laws and sports-specific rule changes, 662–64  
 differences to adult concussion, 647  
 difficulty of estimating true incidence, 646  
 imaging, 658–59  
 immediate assessment, 647–48  
 impact quantification, 664  
 incidence of sport-related concussion, 646  
 influence on cognitive development, 654–55  
 initial signs and symptoms, 647  
 initiatives to reduce risk, 666  
 late effects, 665–66  
 neurobiological tests, 657–58  
 office assessment and neuropsychological evaluation, 655–57  
 pediatric vulnerability, 648  
 persistent post-concussive psychiatric symptoms, 655  
 physical and cognitive rest, 659–62  
 post-concussive symptoms, 652–54  
 prolonged recovery, 650–52  
 repeat injury risk, 649–50  
 second impact syndrome, 650  
 sex differences in outcomes of sport-related concussion, 652  
 subconcussions, 664–65  
 symptom assessment, 657  
 peer support programs, 389  
 Peerless, S.J., 61  
 Penfield, Wilder, 295, 402  
 PER3 gene polymorphisms, 762  
 periaqueductal gray matter, 388  
 peroxyxynitrite, 139  
 persistent deleterious post-traumatic brain change, 535  
 persistent or delayed-onset encephalopathy following repeated CBI structural neuroimaging, 630–31  
 persistent post-concussive psychiatric problems, 384  
 current lack of knowledge about, 422  
 disorders are not unique to post-concussion, 423  
 influence of premorbid status, 423–25  
 most common problems, 425–26  
 occurrence where there are no cognitive problems, 422–23  
 pediatric patients, 655  
 post-concussive aggression, 442–53  
 post-concussive depression, 427–35  
 post-concussive suicidality, 435–42  
 premorbid personality, 423–25  
 review of studies, 425–26  
 persistent post-concussive symptoms (PPCS), 2  
 barriers to understanding, 345–48  
 controversy over, 1–2  
 pediatric patients, 650–52  
 problems with psychological explanations, 345–48  
 personality testing, 403  
 PET (positron emission tomography), 277  
 Petit, Jean Louis, 42  
 phenylketonuria (PKU), 318  
 Phlda1 gene, 145  
 phospho-tau (P-tau) biomarker, 642  
 phrenology, 292–93  
 physiatrists  
 ability to care for concussion survivors, 416  
 physical therapy interventions  
 systematic review of research, 790  
 Pigray, P., 42, 44  
 Pinel, Phillippe, 510  
 pituitary dysfunction  
 biomarker for brain changes, 642  
 pituitary gland  
 anterior pituitary (adenohypophysis) hormones, 767  
 clinical consequences of hypopituitarism, 774  
 effects of concussion in children and adolescents, 773–72  
 effects of repetitive concussion in adults, 772  
 natural history of hypopituitarism, 773–74  
 pathophysiology of trauma injury, 768  
 posterior pituitary (neurohypophysis) dysfunction, 773  
 posterior pituitary (neurohypophysis) hormones, 767  
 prevalence of anterior pituitary dysfunction after TBI, 768–72  
 prevalence of post-traumatic hypopituitarism, 767–68  
 screening protocols for hypopituitarism, 774–75  
 structure and function, 767  
 pituitary hormones  
 clinical consequences of deficiencies, 767–68  
 deficiency after CBI, 767  
 hormone replacement therapies, 775–76  
 Plato, 499  
 polypathology after TBI, 578  
 polypathy  
 labeled as CTE, 527  
 polytrauma triad (pain, PPCS and PTSD), 686  
 Porsolt test, 181  
 Portland Digit Recognition Test (PDRT), 351  
 positivism in medicine, 35  
 Post-Concussion Scale (PC Scale), 653  
 Post-Concussion Symptom Inventory (PCSI), 654, 657  
 Post-Concussion Symptom Scale (PCSS), 657  
 post-concussion syndrome, 210, 292, 320  
 lack of evidence for, 383–84  
 post-concussion syndrome or neurosis (World War II, Korean War), 684  
 post-concussive aggression, 442–53  
 abnormal threat response, 447–48  
 agitation, 444  
 anger, 444  
 cannabinoid intervention, 451–52  
 causes, 446–49  
 defining aggression, 442–43  
 detection and measurement, 444–46  
 effects of marijuana, 451–52  
 epidemiology, 446  
 intermittent explosive disorder (IED), 444  
 irritability, 444, 446  
 kindling hypothesis, 448–49  
 link between TBI and imprisonment, 442  
 management approaches, 449–52  
 management recommendations, 452–53  
 non-pharmacological management, 449–50  
 pharmacological management, 450–52  
 range of terms and concepts used to describe, 443–44  
 risk factors, 446–47  
 post-concussive depression, 427–35  
 causes, 430–32  
 definition of depression, 427  
 detection and measurement, 427–28  
 epidemiology, 428–30  
 functional findings, 431–32  
 management approaches, 432–34  
 management recommendations, 434–35  
 non-pharmacological approaches, 432–33  
 pharmacological approaches, 433–34  
 risk factors, 430–32  
 structural findings, 431  
 post-concussive headache approach to assessment and treatment, 739  
 classification systems, 728  
 classification systems for post-traumatic headache, 730  
 clinical testing, 736  
 evaluation, 735–36  
 future research directions, 739  
 guidelines, 729  
 impairment rating, 738–39  
 inconsistent nomenclature and definitions, 728  
 management, 736–37  
 neurobiology, 729–30  
 neuroimaging, 736  
 neuromedical management, 736–37  
 pathoetiologies, 728, 729–30  
 patient history, 735  
 physical examination, 735–36  
 prognosis, 738  
 psychological management, 737  
 psychological testing, 736  
 rehabilitative management, 736–37  
 risk factors, 728  
 variants, 728  
 post-concussive PTSD-type distress  
 case of Reema, 453, 458  
 causes, 461–65  
 challenging PTSD as a diagnostic entity, 453–57  
 detection and measurement challenges, 458–59  
 disruption of neurocircuits, 463–65  
 effect of an amnesic interval, 457–58  
 epidemiology, 459–61  
 Eye Movement Desensitization and Reprocessing (EMDR), 469–71  
 genetic factors, 461–63  
 imaging, 465–67  
 management approaches, 467–71  
 management recommendations, 471–73  
 neurobiology, 467  
 non-pharmacological management, 468–71  
 pharmacological management, 471



- PTSD-associated symptoms, 457  
 questions relating to, 453  
 post-concussive  
   suicidality, 435–42  
   anatomical and physiological correlates, 441–42  
   barriers to confidence in published conclusions, 435–36  
   detection and diagnosis, 436  
   epidemiology, 436–39  
   factors associated with suicide, 435–36  
   long-term follow-up of brain-injured Finnish soldiers, 435  
   management, 442  
   nature of self-destructive behavior, 435  
   risk factors, 440–41  
   risk in persons with PTSD, 439–40  
 post-concussive  
   symptoms, 383–84  
   pediatric patients, 652–54  
   professional concussion deniers (PCDs), 346–47  
   response bias in symptom reporting, 345–55  
 post-traumatic amnesia  
   significance of, 292  
 Posttraumatic Checklist (PCL), 459  
 post-traumatic cluster headache, 735  
 Posttraumatic Diagnostic Scale, 459  
 post-traumatic headache, 728  
   classification systems, 730  
   headache subtypes, 730–35  
 post-traumatic headache (PTHA), 728  
 post-traumatic migraine, 733–35  
 Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), 459  
 Pott, Percival, 36, 43  
 Pourfour du Petit, Francious, 42  
 prazosin, 763  
 prefrontal circuits  
   disruption by TBI and CBI, 384  
   role in post-TBI mood disorders, 388–89  
 prefrontal cortex  
   role in emotional regulation, 384  
   structural changes in PTSD patients, 392–93  
 pregnancy  
   grey matter volume reduction, 509  
 pre-morbid neuropsychiatric problems  
   influence on CBI outcomes, 335–37  
 Princip, Gavriilo, 51  
 prion protein (PrP<sup>c</sup>), 170–71  
 prion protein (PrP<sup>sc</sup>), 170  
 processing bodies (PBs), 171  
 professional concussion deniers (PCDs), 346–47  
 progesterone, 305  
 prognosis for mTBI  
   World Health Organization view, 14  
 prolactin, 767  
   deficiency symptoms, 768t26.1  
 Prolonged Exposure Therapy (PE), 468, 469  
 propranolol, 385  
 proton Magnetic Resonance Spectroscopy (<sup>1</sup>H MRS), 74–75, 142, 147  
 psychiatrists  
   ability to care for concussion survivors, 416  
 psychoanalysis  
   influence on neuropsychology, 403  
 psychoeducational programs, 449  
 psychosocial risk factors  
   for mood disorders associated with TBI, 387  
 psychotherapy  
   systematic review of research, 788–89  
 PTGS2 gene, 144  
 PTSD (post-traumatic stress disorder), 383  
   amnesia for the traumatic event, 391  
   association with concussion in military personnel, 106  
   changes in the autonomic nervous system (ANS), 392  
   changes in the HPA axis, 392  
   childhood abuse risk factor, 391  
   definition, 390–91  
   distinguishing from mild TBI, 390  
   DSM-5 classification of symptom clusters, 390–91  
   DSM-5 diagnostic criteria, 391  
   emergence after CBI, 303  
   epidemiology of PTSD following TBI, 391  
   functional studies, 393  
   genetic risk factors, 392  
   hormonal risk factors, 391–92  
   incidence among military personnel with TBI, 390  
   incidence following TBI, 391  
   influence of physical injury on PTSD risk, 392  
   management of mTBI plus PTSD nightmares, 763  
   myth of missing traumatic memory, 106–7  
   overlap of symptoms with TBI, 390  
   pathophysiology, 392  
   phenomenological presentation, 390–91  
   rates in military personnel with CBI, 107–8  
   reasons for the CBI/PTSD link, 108  
   response to aversive and safety cues, 392  
   risk factors, 391–92  
   risk of post-concussive suicidality, 439–40  
   structural brain changes overlap with TBI, 392–93  
   treatment, 393–94  
   type of stressors associated with, 390  
 PTSD Checklist for DSM-5, 391, 688  
 PTSD Symptom Scale-Interview Version, 459  
 PTSD-type post-concussive distress  
   case of Reema, 453, 458  
   causes, 461–65  
   challenging PTSD as a diagnostic entity, 453–57  
   detection and measurement challenges, 458–59  
   disruption of neurocircuits, 463–65  
   effect of an amnesic interval, 457–58  
   epidemiology, 459–61  
   Eye Movement Desensitization and Reprocessing (EMDR), 469–71  
   genetic factors, 461–63  
   imaging, 465–67  
   management approaches, 467–71  
   management recommendations, 471–73  
   neurobiology, 467  
   non-pharmacological management, 468–71  
   pharmacological management, 471  
   PTSD-associated symptoms, 457  
   questions relating to, 453  
 Pudenz, R.H., 60  
 punch-drunk syndrome, 529, 639  
 quantitative MRI, 264t6.1  
 quetiapine, 385  
 race/ethnicity and CBI risk, 102  
 Radial Arm Maze, 166  
 Rakic, Pasco, 173  
 ramelteon, 763  
 Rancho Los Amigos Scale of Cognitive Levels, 444  
 Rank, Otto, 403  
 reactive nitrogen species (RNS)  
   generation in CBI, 139–40  
 reactive oxygen species (ROS), 93  
   generation in CBI, 139  
 rebound headache, 734  
 recovery  
   defining for CBI, 78–79  
   inability to define and confirm, 212  
   may actually be behavioral adaptation, 248–49  
   network theory, 556–57  
   three-month myth, 260–61  
 rehabilitation  
   role of environmental enrichment, 306  
 rehabilitation psychologists  
   ability to care for concussion survivors, 417  
 Reitan, Ralph, 403, 406  
 Rennie, Drummond, 15  
 repeated concussions  
   functional neuroimaging, 560–63  
   heterogeneity of late effects, 629–30  
   injury risk in pediatric patients, 649–50  
   investigating the later effects, 527–29  
   MRS studies, 566–67  
   range of brain rattlings defined by, 527–29  
   relationship to tauopathy, 534  
   risk of tauopathy, 534–35  
   sport-related risk, 113  
   structural neuroimaging of persistent or delayed-onset encephalopathy, 630–31  
   vulnerability of the post-concussive brain, 145–47  
   window of metabolic brain vulnerability, 141–42  
 repeated subconcussive trauma  
   neuroimaging, 567  
 research  
   anti-intellectualism in medicine, 803  
   ethical restraints on concussion research, 213–16  
   funding for CBI/TBI research, 4–5  
   insufficient empirical investigation, 3–10  
   lack of a meaningful outcome measure, 11  
   methodology of the Late Effects of Traumatic Brain Injury study, 800–1  
   need for prospective longitudinal studies of concussion, 10, 129, 800–1

## Index

- research (*cont.*)  
 pressing research issues, 8–10  
 TBI research initiatives in the  
 21st century, 6  
 uncertainties which delay  
 understanding of  
 CBI, 802–3  
 response bias in CBI symptom  
 reporting, 345–55  
 reticular activating system  
 (RAS), 757  
 retractions bulbs of Cajal, 61  
 Rewcastle, N.B., 61  
 Rey Auditory Verbal  
 Learning Test (RAVLT,  
 Rey), 409  
 Rey-Osterrieth Complex Figure  
 Test, 21–22  
 Rhazes, 39  
 ribonucleoprotein (RNP)  
 granules, 171–72  
 Richardson, Natasha, 96  
 Risk of Suicide  
 Questionnaire, 436  
 risperidone, 390  
 Rivermead Post-concussion  
 Symptoms Questionnaire  
 (RPSQ), 217, 289, 290,  
 445, 653, 744  
 Rock1 gene, 145  
 rodeo  
 concussion risk, 125–26  
 Rorschach Inkblot Test, 402, 403  
 Rotarod test, 166  
 rotational acceleration in  
 CBI, 139  
 rugby  
 concussion risk, 126  
 Russel, Colin, 55–56  
 Russell, W.R., 56–58  
  
 S100B biomarker, 640, 641, 642  
 Sachs, Hans, 403  
 Scandinavian Neurotrauma  
 Committee (SNC)  
 CT protocol, 602–4  
 Schaller, Walter, 51  
 Scottish Intercollegiate Guides  
 Network (SIGN)  
 guideline on CT scan after  
 concussion, 601  
 second impact syndrome, 103,  
 113, 145–47, 537  
 pediatric patients, 650  
 selective serotonin reuptake  
 inhibitors (SSRIs), 385,  
 389  
 Sensory Organization Test  
 (SOT), 676  
 serotonin–norepinephrine  
 reuptake inhibitors, 389  
 serotonin transporter (5HTT)  
 polymorphisms, 387  
 sertraline, 385, 389  
 serum neurofilament light (NFL)  
 assays, 218  
 sex differences  
 risk of CBI, 101–2  
 sport-related concussion  
 risk, 112–13  
 sex differences in CBI outcome  
 differences observed in  
 concussed brains, 341  
 hysteria explanation, 338  
 pediatric sport-related  
 concussion, 652  
 risk factors, 337–43  
 sexual dimorphism in heads  
 and brains, 338–40  
 vulnerable phase of the female  
 menstrual cycle, 342–43  
 Sh3glb1 gene, 145  
 shear forces in CBI, 139  
 shear injury in TBI, 262–63  
 Shelden, C.H., 60  
 shell shock (World War I),  
 50–52, 53, 104, 684  
 single nucleotide polymorphisms  
 (SNPs), 306, 461  
 Skae, F.M.T., 47  
 skateboarding  
 concussion risk, 126  
 skiing  
 concussion risk, 126  
 SLC6A4L gene, 392  
 sleep disorders after CBI  
 atypical post-CBI sleep  
 disorders, 758–60  
 changes in sleep  
 architecture, 757–58  
 circadian rhythm, 757  
 clinical problems associated  
 with, 761  
 control and regulation of  
 sleep, 757  
 cytokines and sleep, 762  
 distinction from post-  
 concussive fatigue, 756  
 genetic factors, 761–62  
 homeostatic sleep drive, 757  
 hypersomnia, 758  
 hypnagogic/hypnopompic  
 hallucinations, 760  
 importance of sleep for CBI  
 recovery, 756  
 management, 762–63  
 management  
 alternatives, 763–64  
 management of mTBI plus  
 PTSD nightmares, 763  
 melatonin and orexin  
 disruption, 762  
 narcolepsy, 760  
 neurometabolic cascade, 762  
 normal sleep cycle, 757  
 obstructive sleep  
 apnea, 758–60  
 pathophysiology, 760–61  
 prevalence, 758  
 quality of life impacts, 756–57  
 range of sleep disorders, 756  
 REM and NREM sleep, 757  
 role of the autonomic nervous  
 system, 757  
 sleep hygiene, 750–51  
 sleep paralysis, 760  
 Smeaton, John, 803  
 snowboarding  
 concussion risk, 126  
 soccer  
 concussion risk, 126–28  
 effects of deliberate heading of  
 the ball, 126–28  
 social disadvantage  
 brain reserve  
 hypothesis, 356–57  
 component risk factors, 355  
 failure to return to work, 356  
 inequality, 355  
 low education level, 356  
 low occupational status, 355  
 low social standing, 356  
 lower socio-economic status  
 (SES), 356  
 minority status, 355–56  
 neurobiology of, 356–57  
 poor social support, 356  
 poverty, 355  
 race, 355–56  
 risk factor for poor outcome  
 in CBI, 355–57  
 underlying mechanisms of  
 social stress, 355–56  
 unmarried status, 355, 356  
 why it is associated with worse  
 outcome for CBI, 356–57  
 social support  
 role in human CBI  
 recovery, 167  
 Society for Behavioral and  
 Cognitive Neurology, 416  
 somatic symptoms disorder  
 (SSD), DSM-5, 347  
 somatoform disorders, 346  
 SPECT (single photon  
 emission computed  
 tomography), 277  
 spectrin breakdown  
 products (SBDPs)  
 biomarkers, 641  
 aII-spectrin breakdown  
 products (SBDPs), 641  
 Spencer, Herbert, 295  
 Sport Concussion Assessment  
 Tool - 3rd edition  
 (SCAT-3), 675  
 sport-related concussion  
 activity-related differences in  
 risk, 113  
 age-related risk  
 factors, 111–12  
 all-terrain vehicle riding, 114  
 annual rates of concussions in  
 sports, 111  
 approach to diagnosis, 672  
 awareness and responsibility  
 for long-term damage  
 caused, 315–18  
 Balance Error Scoring System  
 (BESS), 673–75  
 barriers to epidemiological  
 knowledge, 109–10  
 baseball, 114  
 basketball, 114  
 bicycling, 114–18  
 boxing, 118  
 cheerleading, 118  
 clinical and laboratory  
 tools, 675  
 Common Data Elements  
 (CDEs) outcome  
 measures, 696  
 diffusion tensor imaging  
 (DTI), 678–79  
 electroencephalography  
 (EEG), 678  
 equestrian sports, 118–19  
 event-related potentials  
 (ERPs), 678  
 football (American  
 style), 119–23  
 functional MRI  
 (fMRI), 678–79  
 gait measures, 677  
 genetic susceptibility in  
 children, 315–18  
 Head Health Initiative, 7  
 ice hockey, 123–24  
 implications of exposing  
 children to likely brain  
 injury, 127–28  
 incidence in pediatric  
 patients, 646  
 karate, 124  
 lack of recognition of the  
 problem of brain  
 injury, 108–9  
 lacrosse, 124–25  
 late effects of pediatric  
 concussion, 665–66  
 legal implication, 127–28  
 limitations of  
 neuropsychological  
 testing, 124  
 martial arts, 124  
 Military Acute Concussion  
 Evaluation (MACE), 673  
 multi-modal concussion  
 assessment battery, 677  
 neurophysiological assessment  
 tools, 677–79  
 neuropsychological  
 testing, 675–77  
 on-field evaluation, 672  
 pressures on athletes not to  
 report concussion and  
 symptoms, 25–26  
 rate of CBI incidence in  
 various sports, 113–17  
 rate of CBI recurrence in  
 various sports, 113–17  
 relative incidence in various  
 sports, 113–14  
 repeat-until-demented  
 cycle, 104  
 risk of recurrence, 103–4  
 risk of recurrent  
 concussions, 113  
 risks associated with APOE  
 genotype, 315–18  
 rodeo, 125–26  
 rugby, 126

- second impact syndrome, 103, 113  
 Sensory Organization Test (SOT), 676  
 sex differences in outcomes in pediatric patients, 652  
 sex differences in risk, 112–13  
 sideline tools, 672–75  
 skateboarding, 126  
 skiing, 126  
 snowboarding, 126  
 soccer, 126–28  
 Sport Concussion Assessment Tool - 3rd edition (SCAT-3), 675  
 sports participation rates, 110–11  
 Standardized Assessment of Concussion (SAC), 673  
 summary of assessment tools, 679–80  
 symptom checklists, 672–73  
 taekwondo, 124  
 virtual reality (VR) testing environment, 676–77  
 why prevalence of brain injury may never be known, 128–29  
 wrestling, 127  
 Sports Concussion Assessment Tool (SCAT), 647–48, 657  
 sports neuropsychology, 411–12  
 Sports Neuropsychology Society, 411  
 Standardized Assessment of Concussion (SAC), 653, 657, 673  
 straw man issue of mind/body dualism, 328  
 stress granules (SGs), 171  
 Stress Inoculation Training (SIT), 449, 469  
 stress vulnerability genes, 312–13  
 Stressful Life Events Screening Questionnaire, 459  
 stretch or strain forces in CBI, 139  
 striatum, 388, 389  
 Strich, Sabrina, 50, 60–61, 262  
 structural MRI, 263–75  
   range of techniques, 264  
 structural neuroimaging, 263  
   future technologies, 633–35  
   near-future technologies, 632–33  
   persistent or delayed-onset encephalopathy following repeated CBI, 630–31  
   potential contributions to TBI management, 635  
   present technologies, 631–32  
 Structured Interview for TBI Diagnosis, 687, 689  
 Stuss, DT, 406  
 subconcussions, 65, 528  
   functional neuroimaging, 564–65  
   neuroimaging of repeated subconcussive trauma, 567  
   pediatric patients, 664–65  
   substance use in TBI patients, 751  
 Suicidal Behaviors Questionnaire–Revised, 436  
 Suicide Ideation Questionnaire, 436  
 suprachiasmatic nucleus (SCN), 757  
 suvorexant, 764  
 SWI (susceptibility weighted imaging), 264t6.1  
 Swiss Watch Theory of Behavioral Neurology, 22, 292–93, 296, 402  
 Symbol Digit Modalities Task (mSDMT), 746  
 Symonds, Charles, 55, 56, 154, 212, 249, 328  
 symptom checklists, 672–73  
 symptoms  
   assessment of pediatric patients, 657  
   denial, 346  
   imaginary/intentional dichotomy, 13–14  
   misplaced faith in a dated trichotomy, 11–14  
   organic/psychological dichotomy, 12–13  
   pressures on athletes not to report, 25–26  
   under-reporting, 353  
 syndrome of inappropriate antidiuresis (SIAD), 773  
 T-maze, 166  
 T-tau biomarker, 640  
 taekwondo  
   concussion risk, 124  
 tau  
   disruption by axonal stretch in TBI, 332–34  
   hyperphosphorylation and aggregation, 639  
   pathology after TBI, 576–78  
   role in neurodegeneration, 168–71  
   as a serum biomarker, 642  
 tau oligomers  
   efforts to mitigate late effects in CBI, 543–44  
   role in late effects of CBI, 543–44  
 tauopathy  
   in CTE, 527  
   inflammatory hypothesis of development, 536  
   relationship to repeated CBI, 534  
   risk in persons exposed to repeated concussions, 534–35  
   role in CTE, 530–32  
   seeding hypothesis of development, 536  
   vascular hypothesis of development, 536  
 TBI Identification Clinical Interview, 687  
 TBI Quality of Life (TBI-QOL) Fatigue Short Form, 748t24.2  
 TDP-43 biomarker, 642  
 TDP-43 proteinopathies, 537–38  
 Tedeschi, C.G., 59–60  
 Tef gene, 762  
 temporomandibular joint dysfunction (TMJD)  
   headache caused by, 731  
 tension-type headache, 732–33  
 testosterone replacement therapy, 776  
 Teuber, Hans-Lucas, 3  
 thalamus, 179, 388  
 Thematic Apperception Test (TAT), 403  
 third occipital nerve headache, 732  
 threat response  
   abnormal response following TBI, 447–48  
 three-month myth, 210–12  
 thyroid stimulating hormone (TSH), 767  
   deficiency symptoms, 768t26.1  
   deficiency treatment, 776  
 time after impact of CBI  
   outcome variance related to, 302–5  
 Trail Making tests, 405  
 transcriptomics, 305–10  
 Transforming Research and Clinical Knowledge in TBI (TRACK-TBI), 710  
 trauma-triggered migraine, 734–35  
 traumatic brain injury (TBI)  
   distinguishing mild TBI from PTSD, 390  
   overlap of symptoms with PTSD, 390  
   structural brain changes overlap with PTSD, 392–93  
 Traumatic Brain Injury Act, 6, 7  
 traumatic encephalopathy  
   classification of TBI-induced neurodegenerative disorders, 578–79  
   etiologies, 582  
   features of, 582  
   lack of clinical diagnostic criteria, 582  
   neuropathology, 582  
   origin of the term, 582  
   original meaning of the term, 526–27  
   terms used to describe, 582  
 traumatic encephalopathy review  
   approach to review of published cases, 582  
   challenges to discovery of diagnostic criteria, 585–91  
   lack of clinical diagnostic criteria, 582  
   limitations of the review process, 585–91  
   method, 583  
   provisional research diagnostic criteria, 585  
   results, 583–85  
 Traumatic Life Events Questionnaire, 687  
 treatment after mTBI  
   appropriate interventions, 780  
   mTBI as a diagnostic construct, 780–81  
   post-concussive symptoms, 781  
   treatment-seeking CBI patients, 781  
 treatment of CBI  
   acute and sub-acute management, 793–94  
   balancing rest versus activity, 794–95  
   fatigue management, 794–95  
   guiding principles for clinical practice, 793–96  
   neurobiology as a guiding principle, 794  
   post-acute assessment, 794  
   prioritizing and treating comorbidities, 795  
   tailoring subsequent treatment to the individual, 795–96  
 treatment research systematic review, 781–82  
   challenge to define evidence-based rehabilitation interventions, 791–93  
   clarifying the construct, 793  
   clinical question, 782  
   cognitive rehabilitation, 783–88  
   determination of practice recommendations, 783  
   discussion, 791–93  
   early brief interventions, 791  
   early single session interventions, 791  
   exercise interventions, 789–90  
   guiding principles for clinical practice, 793–96  
   heterogeneity of the CBI population, 793  
   inclusion/exclusion criteria, 782–83  
   lack of consistent outcome measures, 792  
   methodology, 782  
   mixed, multidisciplinary interventions, 790–91

Index

treatment research systematic review ( <i>cont.</i> )	ubiquitin C-terminal hydrolase-L1 (UHCL1) biomarker, 641	virtual reality (VR) testing environment, 676–77	brains mediate mental functions (1664), 209, 328
physical therapy interventions, 790	United Council for Neurologic Subspecialties (UCNS), 416	Visual Analogue Scale for Fatigue (VAS-F), 748	Witkowski, L., 46
psychotherapy, 788–89	unreported cases of CBI, 96		workers' injury compensation schemes
results, 783–91	estimates of numbers, 100		effects on views of concussion, 47–49
sampling subpopulations, 793		Wailoo, Keith, 25	World Health Organization, 95, 96, 98
search strategy, 782	valproate, 385, 390	Wallace, Alfred Russell, 305	definition of mTBI, 84
sensitivity of assessment measures, 792–93	van Leeuwenhoek, Anton, 45	war neurasthenia (World War I), 684	prognosis for mTBI, 14
study quality evaluation, 783	variable number tandem repeats (VNTRs), 306, 461	war neurosis (World War I), 684	World War I
tricyclic antidepressants (TCAs), 389	Vdac1 gene, 145	water consumption dysregulation after TBI, 751	blast injury victims, 53
Trotter, Wilfred Batten Lewis, 53–54, 55, 57, 58	Vegfa gene, 145	Wechsler, David, 403	head injury casualties, 50–52
Tsc22d3 gene, 145	ventrolateral prefrontal cortex, 388	Weight Drop Acceleration Injury Model (WDAI), 160–61	shell shock, 50–52, 53, 104, 684
tumor necrosis factor (TNF), 762	ventromedial prefrontal cortex, 179	Wernicke, Carl, 293, 296, 401	World War II
twin studies differences in the brains of MZ twins, 294–95	Veterans Administration/Department of Defense (VA/DoD) guideline on CT scan after concussion, 601	Western medicine approach to concussion assessment, 210–12	post-concussion syndrome or neurosis, 684
U.S. Centers for Disease Control, 95	Vietnam Head Injury Study, 6	white matter assessing damage in TBI, 262–63	wrestling concussion risk, 127
CDC Blue Book, 97		spectrum of axonal injuries in CBI, 59–63	Wundt, Wilhelm, 401
definition of concussion, 83		Willis, Thomas	Zangwill, Oliver, 403–4
			ziprasidone, 390